8-K: PDS Biotechnology Unveils Promising Phase 2 Data for HPV16-Positive Cancer Immunotherapy, Initiates Pivotal Trial

PDS Biotechnology Corporation has updated its corporate presentation, highlighting compelling Phase 2 clinical results for Versamune HPV in HPV16-positive recurrent/metastatic head and neck cancer and outlining plans for a pivotal Phase 3 trial.

Summary

• PDS Biotechnology Corporation filed an 8-K to announce an update to its corporate presentation deck on June 25, 2025.
• The company is developing Versamune HPV, an HPV16-targeted T cell immunotherapy, to address HPV16-positive head and neck squamous cell carcinoma (HNSCC), a rapidly growing market projected to be the dominant type of HNSCC by 2030.
• Phase 2 results from the VERSATILE-002 study, combining Versamune HPV with Pembrolizumab (KEYTRUDA), showed a median Overall Survival (OS) of 30 months in patients with HPV16-positive recurrent/metastatic HNSCC.
• This 30-month median OS compares favorably to approximately 12 months published for current standard of care therapies.
• The study also reported a Confirmed Objective Response Rate (ORR) of 35.8% and a Disease Control Rate (DCR) of 77.4%.
• Versamune HPV plus Pembrolizumab was well-tolerated, with 1.6% Grade 4 and 0% Grade 5 treatment-related adverse events.
• The company initiated a pivotal Phase 3 trial (VERSATILE-003) in Q1-2025, with median OS as the primary endpoint, aiming for FDA approval.
• The market potential for HPV16-positive HNSCC is estimated at $4-6 billion in the US and EU, with broader HPV16-positive cancers (including cervical, anal, vaginal, vulvar) representing an $8-10 billion potential.
• PDS Biotechnology holds a broad patent portfolio for its Versamune platform and specific product candidates, with patents extending to 2045.

Sentiment

Score: 8

Explanation: The document presents highly positive Phase 2 clinical data for Versamune HPV, showing a significant improvement in overall survival compared to current standards of care. The initiation of a pivotal Phase 3 trial and the large projected market potential contribute to a strong positive sentiment, despite the inherent risks of clinical development and the need for future financing.

Positives

• Versamune HPV demonstrated a median Overall Survival (OS) of 30 months in Phase 2 for 1L recurrent/metastatic HPV16-positive HNSCC, significantly exceeding the approximately 12 months published for current standard of care.
• The therapy received FDA Fast Track designation in 1L recurrent/metastatic HNSCC, potentially accelerating the development and review process.
• The pivotal Phase 3 trial (VERSATILE-003) was initiated in Q1-2025, indicating rapid progression towards potential market approval.
• The treatment combination of Versamune HPV and Pembrolizumab was well-tolerated, with a low incidence of Grade 3+ treatment-related adverse events (16.1% Grade 3, 1.6% Grade 4, 0% Grade 5).
• The company projects a substantial market potential for HPV16-positive HNSCC at $4-6 billion in the US and EU, and $8-10 billion for all HPV16-positive cancers, indicating significant commercial opportunity.
• PDS Biotechnology possesses a broad and extensive patent portfolio for its Versamune platform and specific product candidates, providing long-term intellectual property protection (e.g., Versamune HPV patent expires not before November 2037, PDS01ADC patent expires not before May 2045).
• The Phase 2 data showed a 35.8% Objective Response Rate (ORR) and a 77.4% Disease Control Rate (DCR), with 20.8% of patients achieving 90-100% tumor shrinkage.

Negatives

• No controlled or comparative studies have been conducted directly between checkpoint inhibitors (like Pembrolizumab) and Versamune HPV, or between EGFR inhibitors and Versamune HPV, making direct comparisons to current standards of care based on historical data.
• A significant portion of patients in the VERSATILE-002 Phase 2 study (60% with CPS < 20, 81.2% with prior treatment) were historical low responders to Pembrolizumab, which could complicate the interpretation of the combination therapy's standalone effect, although the results were still strong.

Risks

• The Company's ability to protect its intellectual property rights.
• The Company's anticipated capital requirements, including its anticipated cash runway and plans for future equity financings.
• The Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, with the risk that raising such capital may restrict operations or require relinquishing rights.
• The Company's limited operating history in its current line of business, making it difficult to evaluate prospects or the likelihood of successful business plan implementation.
• The timing for the Company or its partners to initiate planned clinical trials for Versamune HPV, PDS01ADC, and other Versamune-based product candidates.
• The future success of such clinical trials, including the ability to fully fund disclosed clinical trials.
• The successful implementation of the Company's research and development programs and collaborations, and the interpretation of their results.
• The success, timing, and cost of ongoing and anticipated clinical trials, including the receipt of interim or preliminary results which are not necessarily indicative of final results.
• The Company's ability to continue as a going concern.
• Other factors, including legislative, regulatory, political, and economic developments not within the Company's control.

Future Outlook

PDS Biotechnology is focused on advancing Versamune HPV through its pivotal Phase 3 trial (VERSATILE-003) for 1L recurrent/metastatic HPV16-positive HNSCC, with the primary endpoint being median Overall Survival. The company also plans potential follow-on Phase 3 trials for other HPV16-positive cancers, including locally advanced cervical, anal, penile, HNSCC, vaginal, and vulvar cancers, and exploring combinations with PDS01ADC and ICI for 1/2L recurrent/metastatic HPV16+ cancers.

Management Comments

• The corporate presentation reflects management's strategic focus on addressing the growing incidence of HPV16-related cancers, particularly HPV16-positive HNSCC, through its Versamune HPV immunotherapy.
• Management emphasizes the potential for market leadership due to the compelling Phase 2 clinical results, ease of administration, and tolerability of Versamune HPV.
• The company is committed to advancing its lead product candidate, Versamune HPV, into a pivotal Phase 3 trial, targeting FDA approval based on Overall Survival as a necessary primary endpoint.

Industry Context

The document highlights the rapidly growing incidence of HPV16-positive Head and Neck Squamous Cell Carcinoma (HNSCC), projected to become the dominant type of HNSCC by 2030. This segment presents a significant unmet medical need, as current standard of care therapies for recurrent/metastatic HNSCC, such as Pembrolizumab (KEYTRUDA) alone or in combination with chemotherapy/EGFR inhibitors, have shown limited median overall survival (approx. 12 months). PDS Biotechnology's Versamune HPV aims to provide a superior therapeutic option by specifically targeting HPV16-positive tumors and stimulating a potent T cell immune response, potentially shifting the treatment paradigm for this distinct and growing patient population.

Comparison to Industry Standards

• Versamune HPV + Pembrolizumab demonstrated a median Overall Survival (OS) of 30 months in Phase 2 for 1L recurrent/metastatic HPV16-positive HNSCC.
• This compares favorably to published median OS for current standard of care therapies in recurrent/metastatic HNSCC, which is approximately 12 months.
• Specifically, Pembrolizumab alone (from KEYNOTE-048 study) showed a median OS of 12.3 months.
• Pembrolizumab plus chemotherapy (from KEYNOTE-048 study) showed a median OS of 13.6 months.
• Chemotherapy plus EGFR Inhibitor showed a median OS of 10.3 months.
• The LEAP-010 study, involving Pembrolizumab with or without Lenvatinib, also reported lower OS figures compared to PDS Biotech's Phase 2 results.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation due to strong clinical data, large market opportunity, and progression to pivotal trials. However, potential dilution from future equity financings is a consideration.
• **Patients:** Significant positive impact through a potentially more effective and well-tolerated treatment option for HPV16-positive recurrent/metastatic HNSCC, offering extended survival compared to current standards.
• **Employees:** Positive impact through continued research and development, potential for company growth, and job security.
• **Healthcare Providers:** Provides a promising new therapeutic approach for a challenging cancer type, potentially improving patient outcomes and expanding treatment options.

Next Steps

• Continue patient recruitment for the VERSATILE-003 pivotal Phase 3 trial.
• Conduct interim analyses for the VERSATILE-003 trial.
• Continue survival follow-up for patients in the VERSATILE-003 trial.
• Potentially initiate follow-on Phase 3 trials for other HPV16-positive cancers (e.g., locally advanced cervical, anal, penile, HNSCC, vaginal, vulvar cancers).
• Explore combinations of Versamune HPV with PDS01ADC and ICI for 1/2L recurrent/metastatic HPV16+ cancers.

Key Dates

Recommendation

Keywords

Biotechnology, Immunotherapy, HPV16, Head and Neck Cancer, HNSCC, Versamune HPV, PDSB, Clinical Trials, Oncology, Cancer Treatment, FDA Fast Track, Pembrolizumab, KEYTRUDA